Advertisement


David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions

2018 Gastrointestinal Cancers Symposium

Advertisement

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.



Related Videos

Gastroesophageal Cancer
Gastrointestinal Cancer

Manish A. Shah, MD, on Gastric Cancer: Results From the RAINFALL Trial

Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy i...

Gastroesophageal Cancer
Gastrointestinal Cancer

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implicati...

Gastroesophageal Cancer

Pieter van der Sluis, MD, PhD, on Esophageal Cancer: Results From a Surgical Treatment Trial

Pieter van der Sluis, MD, PhD, of the University Medical Center Utrecht, discusses study findings that compared robot-assisted minimally invasive thoracolaparoscopic esophagectomy ...

Colorectal Cancer
Immunotherapy

Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials

Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respecti...

Hepatobiliary Cancer
Immunotherapy

Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224

Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sora...

Advertisement

Advertisement



Advertisement